Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Boundless Bio (NASDAQ: BOLD) announced that Zachary Hornby, President and CEO, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 p.m. ET in New York.

A live and archived webcast will be available in the Investors > Events & Presentations section of the company website.

News Market Reaction – BOLD

+3.81% 3.7x vol

4 alerts

+3.81% News Effect

+6.8% Peak Tracked

+$961K Valuation Impact

$26M Market Cap

3.7x Rel. Volume

On the day this news was published, BOLD gained 3.81%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $961K to the company's valuation, bringing the market cap to $26M at that time. Trading volume was very high at 3.7x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash & investments: $117.6M Total cash & investments: $127.1M Net loss: $13.9M +5 more

8 metrics

Cash & investments $117.6M As of Sept 30, 2025 (Q3 2025 10-Q)

Total cash & investments $127.1M As of June 30, 2025 (Q2 2025 10-Q)

Net loss $13.9M Q3 2025 net loss (10-Q)

Accumulated deficit $232.9M As of June 30, 2025 (10-Q)

R&D expenses $10.7M Q3 2025 (vs. $14.1M in Q3 2024)

G&A expenses $4.5M Q3 2025 (vs. $4.6M in Q3 2024)

ATM program size $14.5M At-the-market equity program capacity; no shares sold as of Sept 30, 2025

Shares outstanding 22,385,611 As of Oct 31, 2025 (Q3 2025 10-Q)

Market Reality Check

Price: $1.16 Vol: Volume 101,072 is below t...

low vol

$1.16 Last Close

Volume Volume 101,072 is below the 20-day average of 162,124 (relative volume 0.62x). low

Technical Shares at $1.05 are trading below the 200-day MA $1.24 and 58.66% under the 52-week high of $2.54, hovering near the 52-week low of $1.00.

Peers on Argus

BOLD was down 3.67% while close peers showed mixed moves (e.g., ALLR -4.26%, RNT...

BOLD was down 3.67% while close peers showed mixed moves (e.g., ALLR -4.26%, RNTX -6.92%, AKTX +0.70%, NEUP +0.50%), pointing to stock-specific trading rather than a unified biotech sector move.

Historical Context

5 past events · Latest: Jan 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Pipeline advancement	Positive	-0.8%	FDA accepted IND for BBI-940 and extended cash runway into 2H 2028.
Nov 24	Conference participation	Neutral	-1.8%	CEO scheduled for fireside chat at Piper Sandler healthcare conference.
Nov 05	Earnings and updates	Neutral	-3.1%	Reported Q3 2025 results, cash of $117.6M, and BBI-940 IND timeline.
Oct 13	Scientific conference	Positive	+2.4%	Announced AACR-NCI-EORTC poster on BBI-355 and BBI-825 combination data.
Aug 05	Earnings and updates	Neutral	-1.7%	Q2 2025 results, strong $127.1M cash and progress toward BBI-940 IND.

Pattern Detected

Recent news, including clinical and conference updates plus earnings, often saw modest price moves, with mostly aligned reactions and one notable divergence on positive pipeline news.

Recent Company History

Over the past six months, Boundless Bio has highlighted cash runway, pipeline progression, and scientific visibility. Earnings updates on Aug 5, 2025 and Nov 5, 2025 emphasized cash balances above $117M and funding into the first half of 2028, alongside portfolio prioritization. Conference and presentation news, such as the AACR‑NCI‑EORTC poster on Oct 23, 2025 and the Piper Sandler fireside chat, generally produced small moves. The Jan 20, 2026 IND acceptance for BBI‑940 saw a slight negative reaction despite positive operational content, contrasting with today’s routine conference participation news.

Market Pulse Summary

This announcement highlights Boundless Bio’s participation in a Guggenheim biotech summit, continuin...

Analysis

This announcement highlights Boundless Bio’s participation in a Guggenheim biotech summit, continuing a pattern of conference and investor engagement events. Against a backdrop of trading below the 200-day MA of $1.24 and near the $1.00 52-week low, investors may track how management communications complement prior milestones such as the BBI‑940 IND acceptance and reported cash balances above $117M that fund operations into the first half of 2028.

Key Terms

extrachromosomal dna, ecdna, oncogene amplified cancers, phase 1/2, +3 more

7 terms

extrachromosomal dna medical

"oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver..."

Extrachromosomal DNA are pieces of genetic material found inside a cell but outside the cell’s main chromosomes, often as small circular or loose fragments. They can carry copies of genes that drive cell growth and can make tumors behave differently or resist treatments, so for investors they matter because they can influence how effective drugs, diagnostics, or therapies will be and therefore alter risk, timelines and potential value in biotech and healthcare deals.

ecdna medical

"interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative..."

Extrachromosomal DNA (ecDNA) are small, circular pieces of DNA that sit outside a cell’s normal chromosomes and often carry extra copies of genes that drive cell growth. Think of them as sticky notes with repeat instructions that can make a cell behave aggressively; for investors, ecDNA matters because it creates unique disease biology that can change how cancers are diagnosed, how drugs work, and which therapies or diagnostics gain commercial value.

oncogene amplified cancers medical

"therapies to patients with previously intractable oncogene amplified cancers..."

Oncogene amplified cancers are tumors in which certain genes that drive cell growth are present in extra copies, causing those growth signals to be turned up like a duplicated gas pedal. Investors watch these cancers because the presence of gene amplification can make tumors more responsive to targeted drugs or diagnostic tests, affecting the value of therapies, clinical trial success rates, and potential market size for treatments.

phase 1/2 medical

"ceased enrollment in the Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825)..."

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

at-the-market equity program financial

"The company has an at‑the‑market equity program of up to $14.5 million..."

An at-the-market equity program lets a company sell newly issued shares directly into the open market at the current trading price through a broker, rather than in a single, prearranged block. It provides flexible, on-demand access to cash—like drawing small amounts from a credit line—but increases the number of shares outstanding, which can reduce existing shareholders’ ownership percentage and put downward pressure on the stock price, so investors monitor program size and pacing.

schedule 13g/a regulatory

"[SCHEDULE 13G/A] Boundless Bio, Inc. SEC Filing..."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

xenograft models medical

"single-agent tumor regressions in xenograft models and said it expects..."

Xenograft models are laboratory tests in which human tissues or tumors are implanted into animals (commonly mice) so researchers can watch how a disease progresses and how a potential drug behaves in a living body. For investors, these models act like a realistic prototype test: strong positive results can lower the technical risk of a drug program and increase the likelihood of advancing to costly human trials, while failures can signal higher development risk.

AI-generated analysis. Not financial advice.

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026.

The fireside chat session is scheduled for Thursday, February 12, in New York, NY, at 3:00 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Contacts:
James Lee, Boundless Bio
jlee@boundlessbio.com

Investors
Renee Leck
renee@thrustsc.com

FAQ

When will Boundless Bio (BOLD) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

The presentation is scheduled for Thursday, February 12, 2026 at 3:00 p.m. ET. According to the company, Zachary Hornby will participate in a fireside chat in New York, with a live webcast and archived replay available online.

How can investors watch Boundless Bio (BOLD) fireside chat at the February 12, 2026 summit?

Investors can access a live webcast and archived replay via the company's investor website. According to the company, the webcast will be posted under the Investors > Events & Presentations section for streaming and later viewing.

Who from Boundless Bio (BOLD) will speak at the Guggenheim Biotech Summit on February 12, 2026?

Zachary Hornby, President and CEO, will participate in the fireside chat on February 12, 2026 at 3:00 p.m. ET. According to the company, he will discuss the business and recent developments during the session in New York.

Will Boundless Bio (BOLD) provide a replay of the February 12, 2026 fireside chat?

Yes, a replay will be available after the live event via the company website. According to the company, an archived webcast will be posted under Investors > Events & Presentations for on-demand access following the summit.